About
Adsunib is a potent, multi-targeted receptor tyrosine kinase inhibitor (TKI) that exerts its anti-tumor effects by simultaneously blocking several key receptors crucial for tumor growth, angiogenesis, and metastatic dissemination. It specifically inhibits the activity of various tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and KIT, among others. These receptors play pivotal roles in the proliferation and survival of cancer cells, as well as in the formation of new blood vessels that supply tumors with nutrients and oxygen. By broadly inhibiting these critical pathways, Adsunib effectively disrupts multiple facets of cancer progression, leading to reduced tumor growth, decreased tumor vascularization, and inhibition of metastasis. This comprehensive inhibitory profile makes Adsunib an effective treatment option for a range of solid tumors, offering a strategic approach to halt disease progression and improve patient outcomes in advanced settings.
Uses
- Treatment of advanced renal cell carcinoma.
- Management of gastrointestinal stromal tumors (GIST).
- Treatment of pancreatic neuroendocrine tumors.
- Adjuvant therapy in specific oncology settings.
Directions For Use
Take orally once daily for a specified period, followed by a rest period, as directed by your physician. Swallow the capsule whole.
Benefits
- Broad-spectrum anti-tumor activity.
- Inhibits angiogenesis.
- Effective against multiple cancer types.
- Oral administration.
- Potential for improved progression-free survival.
- Offers a treatment option for advanced disease.
Side Effects
- Fatigue
- Diarrhea
- Nausea
- Vomiting
- Hand-foot syndrome
- Hypertension
- Stomatitis
- Dysgeusia
- Skin discoloration
- Thrombocytopenia
- Neutropenia
- Hypothyroidism
Safety Measures
- Alcohol - Limit alcohol intake as it may worsen gastrointestinal side effects or interact with the medication.
- Pregnancy - Contraindicated during pregnancy due to potential for fetal harm. Women of childbearing potential must use effective contraception.
- Breastfeeding - Breastfeeding is not recommended during treatment and for a period after the last dose due to potential harm to the infant.
- Liver - Use with caution in patients with hepatic impairment; monitor liver function closely and adjust dose as necessary.
- Kidney - Use with caution in patients with renal impairment; dose adjustments may be required based on the severity of kidney dysfunction.
- Lung - Monitor for signs of pulmonary embolism or other lung-related adverse events, which can be serious.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!